We anticipate the retail experience evolving,
such that consumers will easily recognize
the unmatched quality of indoor grown cannabis
MONCTON, NB, Nov. 29, 2017 /CNW/ - Drawing on years of
innovation and research, and a deep understanding of the potential
of the cannabis plant, Organigram Holdings Inc. (TSX VENTURE:OGI)
(OTCQB:OGRMF) (the "Company" or "Organigram"), a leading licensed
producer of medical marijuana based in Moncton, New Brunswick, today launched The
Edison Project. The Edison Project is an initiative designed to
produce and offer Organigram patients the very highest quality
flower possible using the latest in technology and industry best
practices.
"The Edison Project represents our very best work to date," says
Ray Gracewood, Organigram's Chief
Commercial Officer. "We're most proud of these strains of medicine
because they're a product of our intensive research on the biology
of cannabis and continuous improvement in production. We've
adopted a culture of refusing to settle at Organigram; it's evolved
such that we've come to discover more about the true potential in
our plants and we've learned how to deliver the benefit of that
potential to our patients."
What's New:
The Edison Project produces cannabis differentiated by three key
characteristics:
- Top flower: In the cannabis world, no part of the plant
is more valuable than the top flower. Lower branches are pruned
frequently throughout the flowering stage to assist the plant in
funneling its energy resources to the top, which helps maximize
robust top flower production. Because they grow at the very highest
point, Edison flowers absorb the most light energy available to the
plant resulting in a more lush flower.
- Hand-manicured: Edison flowers are individually
hand-manicured, a process during which technicians personally
inspect, handle and tailor each one to remove as much stem and
leaf, while retaining as many trichomes as possible. Trimmers
thoroughly inspect each flower and apply the precision and
attention it deserves. Hand-manicured flowers represent the highest
quality whole-flower cannabis produced at the Organigram
facility.
- Craft cured: While growing cannabis to the highest
possible standard is essential, it's only half the story; achieving
exceptional quality depends on how cannabis is cured after harvest.
Intentionally aging with patience and respect for the plant's
evolutionary process results in cannabis that's more complex and
complete. Edison flower is cured in a process which ensures each
strain is treated with the optimal temperature and humidity for its
individual needs. Flowers are cured in small batches and allowed to
breathe longer, resulting in greater chlorophyll breakdown and a
distinct, alluring flavour and aroma.
"At Organigram, we pride ourselves on building a culture of
growth and innovation," says Greg
Engel, CEO, Organigram. "The Edison Project reflects our
commitment to continually evolving our own team's expertise and
delivering a second-to-none cannabis experience for patients. We
anticipate the retail experience evolving, such that consumers will
easily recognize the unmatched quality of indoor grown cannabis and
post-harvest, hand-treated flower. The Edison Project represents
both these elements very well, and we're thrilled to introduce it
to patients."
The first two Edison Project by OGI products – #3 Edison and #7
Edison – are now available to registered patients of Organigram as
of Monday, Nov. 27.
For more information on The Edison Project by OGI, please visit
www.organigram.ca/edison.
About Organigram Holdings Inc.
Organigram Holdings Inc. is a TSX Venture Exchange listed
company whose wholly owned subsidiary, Organigram Inc., is a
licensed producer of medical marijuana in Canada. Organigram is focused on producing the
highest quality, condition specific medical marijuana for patients
in Canada. Organigram's facility
is located in Moncton, New
Brunswick and the Company is regulated by the Access to
Cannabis for Medical Purposes Regulations ("ACMPR").
Organigram has been ranked in the top ten Clean Technology
& Life Sciences Sector on the TSX Venture Exchange 50.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectations. Important factors - including the availability of
funds, consummation of definitive documentation, the results of
financing efforts, crop yields - that could cause actual results to
differ materially from the Company's expectations are disclosed in
the Company's documents filed from time to time on SEDAR (see
www.sedar.com). Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date of this press release. The Company disclaims any intention or
obligation, except to the extent required by law, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
For more information, visit www.Organigram.ca
SOURCE OrganiGram